Table 2. In-vitro anti-proliferative activities of active compounds.
| Compound | IC50 ± Standard Deviation (μM) | |
|---|---|---|
| 3T3 Cell Line | PC3 Cell Line | |
| 1 | 13.1 ± 0.3 | 7.5±0.4 |
| 2 | 23.0 ±1.0 | 7.6±0.4 |
| 3 | 23.5 ± 1.1 | >30 |
| 6 | >30 | >30 |
| 7 | 3.8 ± 0.4 | >30 |
| 8 | >30 | >30 |
| 9 | >30 | >30 |
| 10 | >30 | >30 |
| 11 | >30 | >30 |
| 12 | >30 | >30 |
| 13 | >30 | >30 |
| 14 | >30 | >30 |
| 16 | >30 | >30 |
| 19 | 23.6 ± 0.2 | 9.6±0.3 |
| 22 | 9.2 ± 0.1 | 8.3±0.9 |
| 23 | 15.3 ± 0.9 | 10.5±0.5 |
| 24 | 9.4 ± 0.3 | 6.5 ±0.2 |
| 27 | 26.7 ± 1.0 | >30 |
| 28 | 20.2 ± 0.9 | >30 |
| 29 | 19.5 ± 0.9 | >30 |
| Standard Cyclohexamide) | 0.26 ± 0.1 μM | - |
| Standard (Doxorubicin) | - | 0.91± 0.1 μM |